Mammalian topoisomerase II inhibition activity has been identified in a series of novel pyrazoloquinoline derivatives; potency for two analogues containing cyclohexyl groups at the 2-position was comparable to the reference agents, mAMSA and VP-16. In several instances, topo II inhibition translated to a high level of in vitro cytotoxicity and murine antitumor activity.